You are here: Industry Insights > COVID-19

News List

Samsung Biologics signs Covid-19 therapy manufacturing deal with Lilly pharmaceutical-technology
November 18, 2020
South Korean pharma firm Samsung Biologics has entered a long-term agreement with Eli Lilly and Company to manufacture its investigational Covid-19 virus neutralising antibody, bamlanivimab.
CureVac to Ramp Up Mfg. of COVID-19 Vax Candidate CVnCoV contractpharma
November 18, 2020
Will partner with CDMOs to increase manufacturing capacities for CVnCoV to up to 300 million doses in 2021 and up to 600 million doses in 2022.
India, China may start producing Sputnik V vaccine: Putin expresspharma
November 18, 2020
Putin also proposed that the creation of a vaccine research centre for BRICS countries be sped up.
Cytokine storms play a limited role in moderate-to-severe COVID-19 worldpharmanews
November 17, 2020
Rather than life-threatening hyperinflammation, most adults with moderate-to-severe COVID-19 have a suppressed viral immune response when compared to adults with another viral respiratory infection, influenza. St. Jude Children's Research Hospital and ...
United Sewing Automation Producing USA-Sourced and Manufactured PPE Face Masks in North Carolina prnewswire
November 17, 2020
United Sewing Automation, Inc. (USA) recently welcomed Congressman Patrick McHenry to tour their Mt. Airy, N.C. face mask production factory, one of the only such facilities in the U.S. making American-sourced, surgical grade face masks.
TrippBio Reports Positive Results from Investigator-Initiated Clinical Trial of TD213 for the Treatment of Mild to Moderate COVID-19 Infections prnewswire
November 17, 2020
?TrippBio is dedicated to developing groundbreaking treatments for viral infections, initially targeting COVID-19. TrippBio is developing a patent-pending repurposed FDA-approved drug called TD213.
First COVID-19 patient dosed in Phase II trial of Quellor europeanpharmaceuticalreview
November 17, 2020
The first patient has been dosed with Quellor in a Phase II clinical trial, evaluating the drug for the treatment of pulmonary complications from COVID-19.
Fluvoxamine may prevent severe COVID-19 onset, suggests trial europeanpharmaceuticalreview
November 17, 2020
Researchers say the promising results warrant larger trials evaluating fluvoxamine as a potential intervention to prevent COVID-19 patients developing severe symptoms.
Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment pharmaceutical-business-review
November 17, 2020
Sagent Pharmaceuticals announced that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of Covid-19 in high-risk outpatients and has begun enrolling patients.
￡12.2m boost for coronavirus genomic surveillance pharmatimes
November 17, 2020
The COVID-19 Genomics UK (COG-UK) Consortium is being given ￡12.2 million from the Department for Health and Social Care Testing Innovation Fund to expand whole genome sequencing of positive SARS-CoV-2 virus samples.